Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A
Study Details
Study Description
Brief Summary
This study was divided into four stages: screening period, main trial period, extension period and follow-up period.
In the main trial, both groups received FRSW107 prophylactic therapy. The recommended initial dose of prophylactic administration was 50 IU/kg, the dose range was 25 to 50 IU/kg, and the recommended frequency of administration was once every three days (Q3D). The dose range could be adjusted according to the patient's response. The main trial period was prophylaxis up to ≥50 exposure days (EDs) and ≥6 months.
The investigator may adjust the dose according to the clinical efficacy of the subjects (the occurrence of bleeding and its clinical manifestations) and the concentration of FⅧ valley according to the following principles.
If necessary, the investigator may adjust the dosing interval according to the clinical efficacy of the subject (the occurrence of bleeding and its clinical manifestations) and the concentration of FⅧ. Investigators are advised to inform sponsors or their research partners when adjusting doses and dosing intervals during prophylaxis.
After participants completed prophylaxis until ≥50EDs and ≥6 months, participants' willingness and investigator evaluation were used to decide whether to enter the extended trial. All subjects entering the extended phase continued with the original prophylactic regimen until 100EDs was dosed.
During the main trial period and the extended preventive treatment period, if the subjects have breakthrough bleeding events requiring treatment, hemostatic treatment of breakthrough bleeding with investigational drugs can be performed. The researchers can refer to the treatment guidance for different degrees of bleeding in Table 6-1. Taking into account the subject's prophylactic dose, severity of bleeding, site and extent of bleeding, clinical status, and previous PK results (if any), the investigator determines the appropriate dose to administer (recommended dose range: 25 to 50 IU/kg) and dosing times until the investigator assessed significant control of bleeding episodes (e.g. reduction of pain and swelling) or return to pre-bleeding activity. If the bleeding episode stops, the subject will continue with the same dose and frequency of prophylactic medication as before the bleeding episode.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 3 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: The main test period and the extension period Group 1:≥6 years old and <12 years old; Group 2: <6 years old pediatric patients Preventive treatment: 25~50 is recommendedlU/kg, Q3D, can adjust the dose to 65 IU/kg based on the patient's response, and if necessary, the investigator can adjust the frequency of administration based on the clinical outcome of the subject (the occurrence of bleeding and its clinical manifestations) and the FVIII valley concentration.PK intensive blood collection will be performed for the PK subgroup at V1 (DO) and appropriate PK blood collection will be performed at other specified visit time points. After completion of ∠50EDs and 26 months of treatment, the original prophylactic regimen can be continued until 100EDs |
Drug: FRSW107
experimental：Q3D.≥50EDs， Expansion phase：Q3D.100EDs
Other Names:
|
Outcome Measures
Primary Outcome Measures
- ABR [1year]
Number of bleeding during the treatment period/(Number of treatment days /365.25)
Secondary Outcome Measures
- AJBR [1year]
annual rate of spontaneous joint bleeding and annual rate of traumatic joint bleeding
- AE/ADR [1year]
Frequency and severity of all AE/ADR and SAE/SAR
- Incidence of positive FⅧ inhibitor [1year]
Bethesda method improved by Nijmegen was adopted. Generally, the titers of 20.6 BU/ml were positive for two tests within 1-4 weeks. In addition to the screening period, FV1 inhibitor detection results 137/137Scheme number: SS-107-11103 ConfidentialVersion number: 4.0 Version Date: 07H August 2023The titer was 20.6 BU/ml, and retesting was scheduled within 1-4 weeks. At any visit, a minimum 72-hour FV1 washout period was required before collection of inhibitor test samples.
- Cmax [1year]
Cmax
- Tmax [1year]
Tmax
- FⅧ activity [1year]
FⅧ activity drops to 10%, 5%, 3%, 1% time
Other Outcome Measures
- Functional Independence Score in Hemophilia [1 year]
FISH incorporates items that are perceived as important by persons with hemophilia, is performance based, and is relatively safe to perform.The higher the rating, the better
- Pediatric Quality of Life Inventory [1 year]
The higher the rating, the better
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Children <12 years old, male;
-
Weight >10kg;
-
clinically confirmed patients with severe hemophilia A (defined as confirmation at the time of screening or previous medical records: coagulation factor VI activity <1%);
-
Treated patients, that is, those who had previously received EVI treatment and met the following criteria: <6 years old patients who had been treated with coagulation factor VI for >50 exposure days (EDs250), and < 26 years old patients who had been treated with coagulation factor VI for >150 exposure days(> 150);
-
Normal prothrombin time (PT) or International normalized ratio (INR) <1.3;
-
At least 6 months of treatment and detailed records of bleeding events before screening;
-
The subject's legally authorized representative (i.e. guardian) fully understands and knows about this study and signs the informed consent. Children with the ability to give informed consent (≥8 years old) should be informed and sign the informed consent voluntarily;
Exclusion Criteria:
- People who have been allergic to any component of EVI preparation (including but not limited to mouse or hamster protein or virus vaccine, gene recombination preparation containing mouse or hamster protein, etc.); Those who have had serious adverse reactions to previous vaccine injections or have not recovered from mild to moderate adverse reactions to vaccine injections; 2.Patients with hypersensitivity or anaphylaxis after injection of coagulation factor VI or Fc fusion protein products; 3. Positive factor VI inhibitor at screening (20.6 BU/mL), or previous history of factor VI inhibitor, or family history of inhibitor; 4.the screening results of von Willebrand factor (vWE) antigen were lower than the lower limit of normal value; 5. Severe anemia (hemoglobin <60g/L) at the time of screening; 6. Platelet count <100×10⁹ during screening /L; 7.abnormal liver function: alanine aminotransferase (ALT), or aspartate aminotransferase (AST) >3 times the upper limit of normal (ULN); Serum bilirubin (TBIL>3× ULN; 8. Patients with abnormal renal function: serum creatinine (SCr) >1.5×ULN or according toCreatinine clearance calculated by Cockcroft-Gault formula < 60 mL/min (CTCAE Level 1); 9. hepatitis B virus surface antigen (HBsAg), hepatitis C virus (HCV) antibody, anti-human immunodeficiency virus antibody (Anti-HIV) and anti-treponema pallidum specific antibody (Anti-TP) test has one or more positive; 10. Patients with coagulation dysfunction other than hemophilia A; 11,.have other medical conditions that may increase the risk of bleeding or blood clots; 12. Have a known mental disorder that may affect trial compliance; 13. Patients who have used EV preparations of any standard half-life (e.g., Bekochi, Koyuki, Biinstop, Renjie, etc.) within 3 days or 5 half-lives prior to the first dose; Patients who have used any other half-life extension FVI preparations within 4 days or 5 half-lives prior to dosing (older at the time of retrieval); 14. Patients who have used emesezumab within 6 months prior to first dosing; 15. Severe cardiovascular and cerebrovascular disease, such as cerebral arteritis, moyamoya disease, stroke, viral myocarditis, endocarditis, endocardial fibroplasia, severe arrhythmia, congestive heart failure (New York Heart Association grade
III), uncontrolled hypertension, thromboembolic disease, and uncontrolled diabetes, occurred within 6 months prior to the first medication; 16. Patients who had used monoclonal antibody therapy, Fc fusion protein products, or intravenous immunoglobulin within 3 months before the first dose; 17.those who underwent major surgical procedures and transfusions of blood or blood components within 4 weeks prior to initial dosing, or who plan to undergo elective surgery (other than minor surgery such as tooth extraction) during the study treatment period; Those who underwent major surgical procedures and transfusions of blood or blood components within 4 weeks prior to initial dosing, or who plan to undergo elective surgery during the study treatment period; 18.patients with fever, active infection, allergies (such as allergic rhinitis, allergic asthma, allergic dermatitis, etc.) within 2 weeks prior to the first dose； 19.people with immune deficiency diseases or autoimmune diseases such as systemic lupus erythematosus, or have a history of organ transplantation or stem cell transplantation; Systemic immunomodulators (such as corticosteroids (>10mg/ day equivalent dose of prednisone), alpha-interferon, immunoglobulin, cyclophosphamide, cyclosporin, etc.) used within 14 days prior to the first administration or planned during the study period were allowed to use inhaled, nasal, ocular, intraarticular or topical corticosteroids; 20.patients who were treated with any anticoagulation (other than heparin sealing treatment) or platelet aggregation inhibitors within 7 days prior to initial administration or who required anticoagulation (other than heparin sealing treatment) or platelet aggregation inhibitors during study therapy; 21. Participants who have participated in other clinical trials within 1 month before screening; 22.had other serious medical conditions from which the researchers did not believe they could benefit; He suffered from severe skin disease, which interfered with the observation of local injection reaction.
- Subjects deemed unsuitable by other investigators.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Baoding Hospital, Beijing Children's Hospital Affiliated to Capital Medical University | Baoding | China | ||
| 2 | Children's Hospital Affiliated to Chongqing Medical University | Chongqing | China | ||
| 3 | Guangzhou Women and Children Medical Center | Guangzhou | China | ||
| 4 | Nanfang Hospital, Southern Medical University | Guangzhou | China | ||
| 5 | Affiliated Hospital of Guizhou Medical University | Guizhou | China | ||
| 6 | Children's Hospital, Zhejiang University School of Medicine | Hangzhou | China | ||
| 7 | Anhui Children's Hospital | Hefei | China | ||
| 8 | The Second Affiliated Hospital of Anhui Medical University | Hefei | China | ||
| 9 | Nanjing Children's Hospital | Nanjing | China | ||
| 10 | Affiliated Hospital of Qingdao University | Qingdao | China | ||
| 11 | Shenzhen Children's Hospital | Shenzhen | China | ||
| 12 | Shanxi Children's Hospital | Taiyuan | China | ||
| 13 | Beijing Children's Hospital Affiliated to Capital Medical University | Tianjing | China | ||
| 14 | Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan | China |
Sponsors and Collaborators
- Jiangsu Gensciences lnc.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- SS-107-III03